Grey Matters Health (AGNPD)

OTHER OTC:AGNPD

AGNPD

Grey Matters Health

RESEARCH TOOLSreports

Want to see AGNPD full AI Analyst Report?

Grey Matters Health (AGNPD) Price & Analysis

75 Followers

AGNPD Stock Chart & Stats

$0.05

$0.00(0.00%)

At close: Jan 07 4:00 PM EST

$0.05

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.23 - $0.73

Previous CloseN/A

VolumeN/A

Average Volume (3M)7.73K

Market Cap

$1.79M

Enterprise Value$1.37M

Total Cash (Recent Filing)$210.03K

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.13

Next Earnings

Jul 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding5,418,243

10 Day Avg. Volume2,484

30 Day Avg. Volume7,733

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.77

Price to Sales (P/S)0.00

P/FCF Ratio-1.78

Enterprise Value/Market Cap0.76

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-16.33

Enterprise Value/Ebitda-0.74

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1.35

Revenue Forecast (FY)$817.44K

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetHaving no debt reduces fixed obligations and interest risk, giving management durable financial flexibility to prioritize R&D and clinical programs. This lowers bankruptcy risk, improves resilience across multi-quarter trials, and makes partnership or licensing deals easier without debt overhang.

Improving Cash Burn And Narrowed LossesA materially reduced cash burn and narrower net losses indicates better cost discipline and more efficient capital usage. Persistently improving burn provides a longer runway for clinical milestones, reduces near-term financing pressure, and strengthens the company's ability to reach value-inflecting events before further dilution.

Focused Clinical-stage CNS PipelineA concentrated focus on CNS and repurposed therapeutics builds domain expertise and a clearer regulatory and development pathway. Specialization can lower development execution risk, improve partner interest for licensing, and create a defendable niche positioning versus broad-spectrum peers over multiple quarters.

Bears Say

No Revenue GenerationThe company remains pre-revenue, meaning it cannot self-fund operations or validate commercial demand. Long-term reliance on external financing increases dilution risk, constrains reinvestment capacity, and leaves operations exposed if capital markets tighten or clinical progress slows.

Persistent Negative Operating And Free Cash FlowConsistent negative OCF and FCF signal a structural cash deficit requiring recurring capital raises. Even with improving rates, ongoing burn necessitates continued financing that may dilute stakeholders, limit multi-program advancement, and create execution risk if fundraising timelines slip.

Value Erosion And Negative Returns On EquityVolatile, pressured equity and persistently negative ROE reflect ongoing value destruction from losses. Over time this undermines investor confidence, worsens terms for future capital, and heightens the risk that adverse clinical or regulatory events could materially impair the company's ability to continue operations.

AGNPD FAQ

What was Grey Matters Health’s price range in the past 12 months?

Grey Matters Health lowest stock price was $0.23 and its highest was $0.73 in the past 12 months.

What is Grey Matters Health’s market cap?

Grey Matters Health’s market cap is $1.79M.

When is Grey Matters Health’s upcoming earnings report date?

Grey Matters Health’s upcoming earnings report date is Jul 24, 2026 which is in 82 days.

How were Grey Matters Health’s earnings last quarter?

Grey Matters Health released its earnings results on Apr 29, 2026. The company reported -$0.079 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.079.

Is Grey Matters Health overvalued?

According to Wall Street analysts Grey Matters Health’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Grey Matters Health pay dividends?

Grey Matters Health does not currently pay dividends.

What is Grey Matters Health’s EPS estimate?

Grey Matters Health’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Grey Matters Health have?

Grey Matters Health has 5,418,243 shares outstanding.

What happened to Grey Matters Health’s price movement after its last earnings report?

Grey Matters Health reported an EPS of -$0.079 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.418%.

Which hedge fund is a major shareholder of Grey Matters Health?

Currently, no hedge funds are holding shares in AGNPD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Grey Matters Health

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.